Antacids Market Research, 2032
The global antacids market size was valued at $6.7 billion in 2022 and is projected to reach $9.1 billion by 2032, growing at a CAGR of 3.1% from 2023 to 2032. Antacid is a type of medication that helps to neutralize stomach acid and alleviates symptoms related to excess acid. These medications are available over the counter and contain aluminum, calcium, magnesium, or sodium bicarbonate as active ingredients. They work by reacting with the acid in the stomach to form neutral compounds, which can reduce the acidity of the stomach contents. As a result, antacids can be used to treat symptoms such as acid reflux, heartburn, and indigestion. Antacids are commonly used to relieve symptoms associated with excess stomach acid. They help to neutralize the acid that causes the burning sensation in the chest or stomach.
Market Dynamics
The antacids market is a dynamic and evolving market, influenced by various factors such as changing lifestyles, rise in prevalence of gastroesophageal reflux disease (GERD), and increase in awareness about digestive health among people. The prevalence of GERD is increasing globally, which is a significant driver of the antacids market size. This condition is characterized by the reflux of stomach acid into the esophagus, leading to heartburn and acid indigestion. Antacids provide relief by neutralizing stomach acid and reducing the symptoms of GERD. Thus, as the incidence of GRED increases, the demand for antacids is likely to increase simultaneously, thereby boosting the marker growth.
In addition, unhealthy eating habits; increase in consumption of fast food, alcohol, and tobacco; and sedentary lifestyle are leading to rise in digestive problems, which, in turn, is driving the demand for antacids. Moreover, the availability of over the counter (OTC) antacids is one of the key factors that has contributed to the growth of the antacid market. OTC antacids are easily accessible to consumers without prescription and are widely available in pharmacies and online platforms. This convenience factor has increased the demand for OTC antacids.
Moreover, the availability of a wide range of OTC antacids with different formulations, flavors, and packaging has enabled consumers to choose products that best suit their preferences. This has further boosted the growth of the antacid market, as manufacturers continue to innovate and introduce new formulations, flavors, and packaging to cater to different consumer preferences. This increases the adoption of antacids globally, thus fostering antacids market growth.
However, the emergence of newer and more effective treatments for acid-related conditions such as proton pump inhibitors (PPIs) and H2 receptor antagonists act as a restraint of the antacids market. PPIs and H2 receptor antagonists are prescription medications that work by reducing the production of stomach acid and are more effective than antacids in treating conditions such as GERD and peptic ulcers. PPIs and H2 receptor antagonists have been found to be highly effective in preventing acid-related symptoms and are associated with fewer side effects compared to antacids. This has led to a shift toward the use of these medications, particularly for long-term treatment of acid-related conditions. This is anticipated to hinder the growth during antacids market forecast.
On the other hand, a change in lifestyle could increase the demand for antacids. Lifestyle factors such as diet high in fatty or spicy foods, alcohol consumption, smoking, stress, and lack of exercise can all contribute to increase in acid reflux and heartburn, which are common conditions that antacids are used to treat. For example, people consuming more fatty or spicy foods, or increase in alcohol intake, may experience more frequent episodes of acid reflux and heartburn, leading to higher demand for antacids.
The COVID-19 pandemic has had a significant impact on antacids industry, with increased demand for antacids due to the rising prevalence of gastrointestinal symptoms, including heartburn and acid reflux, among people with COVID-19. The National Library of Medicine (NLM) reported that the prevalence of gastrointestinal symptoms was significantly higher during the pandemic, with a higher percentage of people experiencing heartburn and other related symptoms compared to the previous year. As a result of this increased demand for antacids, the market witnessed a surge in sales during the pandemic.
On the other hand, the disruption of supply chains and distribution channels has caused delays and shortages in some regions. The lockdowns and restrictions on movement and trade have made it difficult for manufacturers to source raw materials and transport finished products, which has led to a decrease in supply and an increase in demand for antacids. Despite the negative impact of the pandemic, several countries have implemented strategies that have helped to regularize the supply chain of medications and medical devices, including antacids. This is anticipated to boost the antacids industry during the forecast period.
Segmental Overview
The antacids market is segmented into mechanism of action, formulation type, distribution channel, and region. By mechanism of action, the market is bifurcated into systemic antacids and non-systemic antacids. On the basis of formulation type, the market is segregated into tablets, liquids, and others. Depending on distribution channel, it is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Mechanism of Action
The non-systemic antacid market held the largest share of the market in terms of revenue in 2022. The growth of the segment is attributed to a rise in awareness among the population regarding non-systemic antacids and the availability of a variety of non-systemic antacid products such as chewable tablets, liquids, and effervescent tablets in the market. In addition, the same segment is anticipated to grow at the fastest rate during the forecast period. This is attributed to the fact that as consumers become more informed about the benefits of non-systemic antacids, they are more likely to choose these products over systemic antacids or other acid-reducing medications. This is anticipated to boost the growth of the non-systemic antacid segment.
By Formulation Type
On the basis of formulation type, the tablets segment dominated the antacids market share in 2022, as antacid tablets are a popular choice for consumers due to their convenience, wide availability, and availability of a range of flavors and formulations. In addition, major players in the market offer a variety of antacid tablet products, which contributes to the dominance of the segment in the market. Moreover, the development and launch of chewable antacid tablets has boosted the popularity of tablets segment.
On the other hand, the liquid segment is anticipated to grow at the fastest rate during the forecast period. Liquid antacids are becoming increasingly popular due to their ease of use and convenience, as they can be quickly and easily swallowed and are suitable for on-the-go use. In addition, the availability of a wide range of flavors has made liquid antacids highly palatable for consumers of all ages. Moreover, liquid antacids are often preferred by children and elderly patients who may have difficulty in swallowing tablets or capsules. This trend is expected to continue to drive the growth of the liquid segment in the antacid market.
By Distribution Channel
On the basis of distribution channel, the drug store & retail pharmacies segment dominated the market in terms of revenue in 2022, owing to the convenience offered to consumers and wide availability of antacids in these settings. In addition, many people prefer to purchase antacids over the counter for occasional heartburn or indigestion rather than seeking a prescription medication or medical intervention, which further boosts the growth of the segment.
On the other hand, the online providers segment is anticipated to grow at a fastest rate during the forecast period due to the increase in popularity of e-commerce websites and online purchasing of medications. The convenience of online purchasing, along with heavy discounts and doorstep delivery services offered by these sites, is expected to drive the growth of the online provider's segment.
By Region
The antacids market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major antacids market share of the antacids market in 2022 and is expected to maintain its dominance during the forecast period. The growth in North America is attributed to the availability of well-developed healthcare infrastructure, presence of majority of key players, rise in incidences of heart burn cases, and easy availability of over-the-counter medication in this region. In addition, the U.S. and other major countries in North America have a high prevalence of gastrointestinal diseases such as GERD, peptic ulcer disease, and gastritis, which drives the demand for antacid medications.
Asia-Pacific is expected to grow at the highest rate during the forecast period due to the presence of pharmaceutical companies in the region and increase in purchasing power of populous countries such as China and India. In addition, rise in healthcare expenditure and surge in awareness among people about heart burn are expected to drive market growth. Furthermore, the growing geriatric population in the region is expected to drive the demand for antacid medications, as older adults are highly susceptible to gastrointestinal diseases.
Competition Analysis
Competitive analysis and profiles of the major players in the antacids market, such as Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd., Bayer AG, Haleon Plc, Infirst Healthcare Inc., Pfizer Inc., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group PLC, and WellSpring Pharmaceutical Corporation are provided in this report. There are some important players in the market such as Major Pharmaceuticals, Topco Associates, LLC, and others.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antacids market analysis from 2022 to 2032 to identify the prevailing antacids market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the antacids market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global antacids market trends, key players, market segments, application areas, and market growth strategies.
Antacids Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 9.1 billion |
 Growth Rate | CAGR of 3.1% |
 Forecast period | 2022 - 2032 |
 Report Pages | 249 |
 By Mechanism of Action |
|
 By Formulation Type |
|
 By Distribution channel |
|
 By Region |
|
 Key Market Players | Cipla Ltd, Pfizer Inc., Alkem Laboratories Ltd., WellSpring Pharmaceutical Corporation, Reckitt Benckiser Group PLC, Infirst Healthcare Inc., Abbott Laboratories, Haleon plc, Bayer AG, Prestige Consumer Healthcare Inc. |
Analyst Review
Antacids are gaining high traction in the market due to alarming rise in prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and other conditions.
The rise in demand for over-the-counter antacids from developed as well as developing regions has largely contributed toward the market revenue in 2022, and is expected to maintain this trend throughout the forecast period. In addition, key market players are focusing on the development of new antacids that are easily accessible and are of low cost, thereby increasing their adoption, globally. Moreover, changes in lifestyle, smoking, changes in sleeping pattern, and unhealthy eating habits are the major factors causing acidity and gastrointestinal disorders, which is anticipated to drive the demand for antacids.
North America is expected to witness highest growth, in terms of revenue, owing to easy accessibility of antacid through well-established distribution channels and shift of people toward self-medication for managing heartburn and indigestion. However, Asia-Pacific is anticipated to witness notable growth during the forecast period due to surge in demand for antacids and unmet medical need of large population in this region.
Asia-Pacific has the highest growth rate in the market with highest CAGR owing to the presence of high population base and surge in geriatric population suffering from gastrointestinal disorders.
Antacid is a medication that is used to alleviate heartburn and indigestion. These medications act by reducing the amount of hydrochloric acid secreted in the stomach.
Key factors driving the growth of the antacids market includes the increase in prevalence of acid reflux and GERD, easy availability of OTC antacids and surge in demand for antacids among geriatric population.
The non-systemic antacids segment exhibited highest growth in terms of revenue in 2022, and is anticipated to continue this trend during the forecast period. This is attributed to the advantages offered by the non-systemic antacids over the systemic antacids.
Major players that operate in the antacids market are Abbott Laboratories, Pfizer Inc., Prestige Consumer Healthcare Inc., Cipla Ltd, Reckitt Benckiser Group PLC, Haleon plc, Bayer AG, Alkem Laboratories Ltd., WellSpring Pharmaceutical CorporationInfirst Healthcare Inc.
The base year is 2022 in antacids market.
The forecast period for antacids market is 2023 to 2032.
The market value of antacids market in 2032 is $9068.47 million.
The total market value of antacids market is $6678.82 million in 2022.
Loading Table Of Content...
Loading Research Methodology...
